The World Health Organization (WHO) would like to announce an upcoming Guideline Development Group meeting for the update on TB treatment and care.
Recent evidence from clinical trials and operational research has emerged on new combination treatments for MDR/RR-TB and pre-XDR-TB that the WHO Guideline Development Group has not yet reviewed. These include 6-month regimens with bedaquiline, delamanid, linezolid, and clofazimine (endTB-Q and BEAT-TB South Africa trials), as well as updated data on 6-month BPaL and BPaLC regimens (more complete data from the TB-PRACTECAL and other operational research studies) for the treatment of patients with MDR/RR-TB with quinolone resistance. Additionally, new trial evidence on nurse-led palliative care for DR-TB patients provides an opportunity to update the chapter on TB care and support.
The overall goal of this GDG meeting is to address additional areas related to the use of new TB drugs and regimens for the treatment of drug-resistant TB for which new evidence became available in 2025, helping countries achieve the global targets of the Sustainable Development Goals (SDGs) and the WHO End TB Strategy.
The objectives are to review evidence on:
- efficacy and safety of novel 6-month regimens for patients with MDR/RR-TB or pre-XDR-TB;
- effectiveness of nurse-led palliative care package for patients with MDR/RR-TB.
To address the additional areas related to the use of new TB drugs and regimens for the treatment of drug-resistant TB, and palliative care intervention for patients with MDR/RR-TB, WHO’s department for HIV, Tuberculosis, Hepatitis and Sexually Transmitted Infections will convene a Guideline Development Group meeting from 24-28 November 2025, in Geneva, Switzerland.
Find more detailed information here.